ARROWHEAD PHARMACEUTICALS, INC. Payments of Debt Issuance Costs
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Payments of Debt Issuance Costs of $18.72 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2026-06-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2026-03-31 was $18.72M.
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2025 was $5.00M, a 59.54% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2024 was $3.13M.
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2023 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2022 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $18.72M derived: sum of 2 quarters · filed 2026-08-04 | $18.72M 10-Q · filed 2026-08-04 | $18.72M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $18.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $18.72M 10-Q · filed 2026-05-07 | $18.72M derived: sum of 3 quarters · filed 2026-05-07 | $18.72M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 10-Q · filed 2026-02-05 | $0.00 derived: sum of 2 quarters · filed 2026-02-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $5.00M 10-K · filed 2025-11-25 |
| 2025-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $5.00M 10-Q · filed 2026-08-04 | $8.13M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $5.00M 10-Q · filed 2026-05-07 | $8.13M derived: sum of 3 quarters · filed 2026-05-07 | $8.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.00M 10-Q · filed 2026-02-05 | $8.13M derived: sum of 2 quarters · filed 2026-02-05 | $8.13M derived: sum of 3 quarters · filed 2026-02-05 | $8.13M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $3.13M derived: sum of 2 quarters · filed 2025-11-25 | $3.13M derived: sum of 3 quarters · filed 2025-11-25 | $3.13M 10-K · filed 2025-11-25 |
| 2024-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | $0.00 derived: sum of 2 quarters · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | $0.00 10-Q · filed 2025-05-12 | ||
| 2023-12-31 | $0.00 10-Q · filed 2025-02-10 | |||
| 2023-09-30 | $0.00 10-K · filed 2025-11-25 | |||
| 2022-09-30 | $0.00 10-K · filed 2024-11-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |